Medicus Pharma has confirmed the 200-microgram dose of its SkinJect patch for further studies targeting Gorlin syndrome, with FDA approval for a pivotal trial underway. The company is also exploring an out-licence for nodular basal cell carcinoma and highlights a potential partnership opportunity for SkinJect. Additionally, Medicus Pharma is advancing a co-development deal with Pfizer on a CD228-targeted antibody-drug conjugate for melanoma and solid tumors, supported by $2 million in funding. These developments position Medicus Pharma as a precision oncology biotech with several upcoming catalysts including patient recruitment and program advancements.
Australian brand STYLD. has partnered with Mattel to release a limited-edition Barbie-themed Christmas collection featuring summer-inspired, reusable entertaining items in Candy Cane Pink and Peppermint Green. The collection includes insulated carafe...
Ether (ETH) increased from $2,452 to $2,508 within four hours, gaining 2.25% by late October 12. During this period, short liquidations on Binance, Bybit, and OKX totaled $5.53 million, significantly outpacing long liquidations of $10,000. Despite th...
The BAT token experienced a significant intraday rise of 16.45%, reaching $0.1753 and marking a 124% increase since September 13 when it closed at $0.0784. The token hit an intraday high of $0.1759 and gained about 11.6% in the past 24 hours. This st...
A large investor (whale) withdrew 600,005 Uniswap (UNI) tokens from Binance, raising their total accumulated position to 1,292,895 UNI since October 11. The latest withdrawal was worth about $4.28 million, with an average acquisition price of $7.42 p...
Celestia's TIA token surged 10.04% within one hour to $0.579282, showing strong short-term volatility despite a 1.96% decline over the past 24 hours. The token traded between $0.506365 and $0.605903 during the day, with a 24-hour trading volume of ov...
